ADC Therapeutics Announces FDA Approval of ZYNLONTA™ (loncastuximab tesirine-lpyl) in Relapsed or Refractory Diffuse Large B-Cell LymphomaBusiness Wire • 04/23/21
ADC Therapeutics SA (ADCT) CEO Chris Martin on Q4 2020 Results - Earnings Call TranscriptSeeking Alpha • 03/18/21
ADC Therapeutics Reports Fourth Quarter and Year-End 2020 Financial Results and Provides Business UpdatesBusiness Wire • 03/18/21
ADC Therapeutics to Host Fourth Quarter and Year-End 2020 Financial Results Conference Call on March 18, 2021Business Wire • 03/11/21
ADC Therapeutics to Participate in Guggenheim Healthcare Talks 2021 Oncology DayBusiness Wire • 02/05/21
ADC Therapeutics Completes Enrollment in Pivotal Phase 2 Clinical Trial of Camidanlumab Tesirine (Cami) in Relapsed or Refractory Hodgkin LymphomaBusiness Wire • 02/04/21
ADC Therapeutics Initiates Expanded Access Program for Loncastuximab Tesirine in the U.S.Business Wire • 01/07/21
ADC Therapeutics and Overland Pharmaceuticals Announce Formation of Overland ADCT BioPharma to Develop and Commercialize Lonca and other ADCs for Hematologic and Solid Tumor Indications in Greater China and SingaporeBusiness Wire • 12/14/20
ADC Therapeutics Announces Updated Clinical Data on Lead Antibody Drug Conjugate Programs Loncastuximab Tesirine (Lonca) and Camidanlumab Tesirine (Cami) Presented at 62nd American Society of Hematology Annual MeetingBusiness Wire • 12/07/20
ADC Therapeutics to Host Conference Call Highlighting Data from its Next-Generation Antibody Drug Conjugates Being Presented at the 62nd American Society of Hematology Annual MeetingBusiness Wire • 11/30/20
ADC Therapeutics Announces FDA Accepts Biologics License Application and Grants Priority Review for Loncastuximab Tesirine for Treatment of Relapsed or Refractory Diffuse Large B-cell LymphomaBusiness Wire • 11/20/20
ADC Therapeutics' (ADCT) CEO Chris Martin on Q3 2020 Results - Earnings Call TranscriptSeeking Alpha • 11/12/20
ADC Therapeutics Reports Third Quarter 2020 Financial Results and Provides Recent Business HighlightsBusiness Wire • 11/12/20
ADC Therapeutics to Host Third Quarter 2020 Financial Results Conference Call on November 12, 2020Business Wire • 11/05/20
ADC Therapeutics Announces Eight Presentations on Data from its Next-Generation Antibody Drug Conjugates at the 62nd American Society of Hematology Annual MeetingBusiness Wire • 11/04/20
ADC Therapeutics Announces First Patient Dosed with Camidanlumab Tesirine (Cami) in Combination with Pembrolizumab in Ongoing Phase 1b Clinical Trial in Selected Solid TumorsBusiness Wire • 11/03/20
Genmab and ADC Therapeutics Announce Amended Agreement for Camidanlumab Tesirine (Cami)GlobeNewsWire • 10/30/20